4basebio PLC and Genezen have expanded their partnership. The companies will give drug developers access to cutting edge synthetic DNA technologies for viral vector manufacturing. 4basebio creates enzymatically produced cell free DNA for next generation genetic medicines. Genezen, by contrast, is a viral vector contract development and manufacturing organization (CDMO). The companies intend to jointly support gene therapy programs through multiple stages of development.
The expanded agreement remains non-exclusive. It will provide drug developers with access to 4basebio’s Research Use Only, High-Quality, and GMP-grade hpDNA® products. These solutions can support development activities and clinical programs.
Synthetic DNA Supports Viral Vector Development
Through the collaboration, Genezen will offer access to 4basebio’s synthetic DNA technology. The technology was developed specifically for viral vector applications. As a result, developers can pursue a more streamlined path toward clinical development. The collaboration combines 4basebio’s DNA manufacturing capabilities with Genezen’s viral vector expertise. Therefore, developers can access complementary technologies through a coordinated development approach.
4basebio uses an enzymatic, cell-free DNA manufacturing process. This process removes bacterial backbone sequences from the DNA starting material. It also eliminates antibiotic resistance genes from the starting material. Furthermore, the approach can support greater efficiency during AAV production. 4basebio reported that its hpDNA template has demonstrated comparable titers to plasmid DNA. However, the template requires approximately 30% less DNA mass.
The technology also requires less transfection reagent during the production process. Consequently, developers can reduce material requirements and associated costs. The approach can also support process efficiency and future manufacturing scalability.
Cell-Free DNA May Reduce Manufacturing Timelines
The cell-free manufacturing model also offers added advantages for genetic medicine developers. Traditional plasmid manufacturing can take longer to produce. Cell-free DNA manufacturing, by contrast, has the potential to greatly reduce the time required to produce DNA. The advance may enable developers to more efficiently move from sequence design to manufacturing of viral vectors. It also may allow for faster progress toward clinical development.
Also, faster DNA production helps developers better manage development timelines. This continues to be a critical factor as cell and gene therapy programs advance through their development stages. The partnership also signals increasing interest in synthetic DNA for making genetic medicines. Manufacturing technologies that enable quality, scalability and reliability are increasingly needed by developers.
Therefore, combining synthetic DNA with established viral vector manufacturing expertise can provide a broader development pathway. The partnership seeks to address these needs from early development through clinical and commercial manufacturing.
Christine Wolosin, Chief Commercial Officer at 4basebio, added: “This partnership reflects our commitment to pairing our proprietary DNA technology with partners who share our dedication to safety, quality, and reliability. Genezen’s leadership in viral vector manufacturing, combined with the growing demand we’re seeing from drug developers for our DNA molecules, speaks to where this industry is heading where synthetic DNA is becoming a critical enabler of genetic medicine. 4basebio is focused on giving drug developers a manufacturing platform upon which they can confidently build their clinical programs.”
The statement highlights the companies’ focus on safety, quality, and reliability. It also points to the growing role of synthetic DNA within genetic medicine. Additionally, the collaboration aligns 4basebio’s proprietary technology with Genezen’s manufacturing capabilities. This combination can help drug developers build clinical programs on a dedicated DNA manufacturing platform.
Genezen Focuses on Scalable Manufacturing Strategies
Susan D’Costa, Chief Technical and Commercial Officer at Genezen, added: “As the cell and gene therapy field continues to mature, developers need manufacturing solutions that not only address today’s challenges, but are designed with the needs of later-stage development in mind. 4basebio’s approach to synthetic DNA represents an exciting advancement in the tools available to viral vector developers. By combining innovative technologies with deep process and manufacturing expertise, we have an opportunity to help developers build more efficient, scalable manufacturing strategies from the outset—and keep the focus where it belongs: advancing therapies for patients.”
Genezen highlighted the significance of developing scalable and standard solutions for later-stage development. As cell and gene therapy programs progress, developers require scalable manufacturing strategies. Furthermore, the partnership harnesses cutting-edge manufacturing and technological expertise. This approach may help developers to create efficient processes from the ground up. The enhanced collaboration will increase overall access to synthetic DNA for viral vector development. It also helps address the broader needs of cell and gene therapy developers.
Under the partnership, 4basebio and Genezen will work together to help drug developers advance their programs more efficiently. The partnership covers early development, clinical manufacturing and commercial manufacturing. With the increasing demand for genetic medicines, manufacturing technologies will continue to be critical. Therefore, synthetic DNA and cell-free production techniques could be important for future viral vector manufacturing.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: GlobeNewswire.com
